0.2400
08-10月-24 09:32:51
15 分の遅延
株式
-0.0150
-5.88%
本日の幅
0.2370 - 0.2599
ISIN
N/A
ソース
NASDAQ
IN8bio Completes Dosing of First Cohort in Phase 1 Clinical Trial with Allogeneic Gamma Delta T-Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant
11 8 2021 07:00:01 提供 Nasdaq GlobeNewswire
IN8bio Appoints Emily Fairbairn and Luba Greenwood to Board of Directors
04 8 2021 07:00:01 提供 Nasdaq GlobeNewswire
IN8bio Announces Pricing of Initial Public Offering
30 7 2021 06:00:00 提供 Nasdaq GlobeNewswire